Dec 03, 2021
VIRALEZE™ distribution agreement and launch in Vietnam (ASX Announcement)
- Starpharma has now signed a 5-year supply and distribution agreement for VIRALEZE™ antiviral nasal spray in Vietnam
- The agreement includes a minimum commitment of at least 1 million units in the first year
- VIRALEZE™ is scheduled to be officially launched in Vietnam today, following its registration for sale this week
- VIRALEZE™ is a broad-spectrum antiviral nasal spray that contains SPL7013, which has been shown to have potent antiviral and virucidal activity in multiple respiratory viruses, including inactivation of >99.9% of the Delta variant of SARS-CoV-2, in laboratory studies that have been published in international, peer reviewed journals
Melbourne, Australia; 3 December 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has signed an ongoing distribution arrangement for VIRALEZE™ antiviral nasal spray in Vietnam with Australian-based Healthco Australia Pty Ltd (HealthCo), with Vietnam-based Truong Bao Land (TBL), and Nam Thanh Trade and Medical Services Company Limited (NTM) responsible for importation and distribution locally in Vietnam. The distribution agreement includes a minimum commitment of at least 1 million units of VIRALEZE™ in the first year. The official product launch is scheduled to occur in Vietnam today following registration of VIRALEZE™ announced earlier this week.
This ongoing agreement with HealthCo is exclusive for Vietnam and follows an initial supply contract for VIRALEZE™ signed in October. This new agreement incorporates a commitment to purchase a minimum of at least 1 million units of VIRALEZE™ in the first year, with ongoing performance obligations. The agreement has an initial five-year term with provision for annual extensions. Starpharma will supply VIRALEZE™, with TBL and NTM responsible for sales, distribution, and marketing of the product locally in Vietnam.
VIRALEZE™ will be available in Vietnam to retail consumers, clinics, hospitals and pharmacies through the local medical distribution networks in Vietnam. Vietnam, which has a population of approximately 98 million, is experiencing a significant Delta outbreak with just over half of its population vaccinated.
Dr Jackie Fairley, Starpharma CEO commented: “We are delighted to see our partners launch VIRALEZE™ in Vietnam so rapidly, particularly given the current Delta outbreak across the country. Starpharma continues to advance its discussions with potential commercial partners elsewhere in multiple countries in Europe, Asia, the Middle East, and India.”
VIRALEZE™ is a broad-spectrum antiviral nasal spray. The antiviral agent in VIRALEZE™, referred to as SPL7013, has been shown to have potent antiviral and virucidal activity in multiple respiratory viruses and multiple variants of SARS-CoV-2, including inactivation of >99.9% of the highly infectious Delta variant, in laboratory studies. VIRALEZE™ is applied in the nose to provide a physical barrier - between viruses and the nasal mucous membrane - that traps and irreversibly inactivates virus. Importantly, VIRALEZE™’s mechanism of action means that mutations of the spike protein that make SARS-CoV-2 more infectious, as occurred for the Delta strain, appear to make the virus more susceptible to trapping and blocking by SPL7013.
VIRALEZE™ is registered in Europe, Vietnam, India and New Zealand, and available in certain markets online. In addition to the supply and distribution arrangements in Vietnam, VIRALEZE™ is also partnered with LloydsPharmacy in the UK, ADMENTA Italia Group in Italy, and Starpharma is in advanced discussions with potential commercial partners in other countries. VIRALEZE™ is not registered for sale or supply in Australia.
Starpharma acknowledges the $1 million in funding for the development of VIRALEZE™ provided by the Australian Government’s Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program, with support from UniQuest. Delivered by MTPConnect, the Australian Government's BTB program is a $22.3 million MRFF initiative that provides up to $1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to proof of concept to turn innovative medical ideas into reality
VIRALEZE™ Antiviral Nasal Spray
VIRALEZE™ contains SPL7013, which has been shown in laboratory studies to inactivate a broad spectrum of respiratory/cold viruses, including multiple SARS-CoV-2 variants, influenza, and RSV. VIRALEZE™ is registered for sale in Europe, Vietnam, India and New Zealand. VIRALEZE™ is not registered for sale or supply in Australia.
SPL7013 is also included in other products registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, Australia and New Zealand.
Download full announcement here: VIRALEZE™ distribution agreement and launch in Vietnam (PDF 224KB)